ORPOF (OSE Immunotherapeutics) Other Current Receivables: $0.69 Mil (As of Dec. 2025)


ORPOF OSE Immunotherapeutics SA ORPOF
41 GF Score
Price $4.43
GF Value $1.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Other Current Receivables?

OSE Immunotherapeutics ORPOF 41 Other Current Receivables is $0.69 Mil as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $1.76 (Significantly Overvalued). The stock has 6 warning signs investors should review.

OSE Immunotherapeutics's Other Current Receivables for the quarter that ended in Dec. 2025 was $0.69 Mil.

OSE Immunotherapeutics's quarterly Other Current Receivables declined from Dec. 2024 ($0.43 Mil) to Jun. 2025 ($0.41 Mil) but then increased from Jun. 2025 ($0.41 Mil) to Dec. 2025 ($0.69 Mil).

OSE Immunotherapeutics's annual Other Current Receivables declined from Dec. 2023 ($0.90 Mil) to Dec. 2024 ($0.43 Mil) but then increased from Dec. 2024 ($0.43 Mil) to Dec. 2025 ($0.69 Mil).

OSE Immunotherapeutics Other Current Receivables Related Terms

OSE Immunotherapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Other Current Receivables Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 0.59 0.90 0.43 0.69

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.72 0.43 0.41 0.69
ORPOF
41GF Score
OSE Immunotherapeutics SA ORPOF
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.69 Mil mean?
OSE Immunotherapeutics (ORPOF) has a Other Current Receivables of $0.69 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' Other Current Receivables too high?
OSE Immunotherapeutics' current Other Current Receivables is $0.69 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Other Current Receivables compare to VRTX and REGN?
OSE Immunotherapeutics' Other Current Receivables of $0.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Other Current Receivables is $0.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.76, compared to a current price of $4.43 — trading 151.7% above its estimated fair value. The current Other Current Receivables is $0.69 Mil. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Other Current Receivables is $0.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 151.7% above its estimated GF Value™ of $1.76. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Other Current Receivables: $0.69 Mil
  • GF Value™: $1.76 vs. price of $4.43 (151.7% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score

Get the complete analysis for ORPOF

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$1.76
GF Value